Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
This product will be manufactured at Lupin’s Nagpur facility in India
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
Subscribe To Our Newsletter & Stay Updated
